RefinedPractice
New OHE Publication Compares 3L and 5L Versions of EQ-5D as Measures of General Population Health
10 November 2015
New publication by OHE’s Yan Feng, Nance Devlin and Mike Herdman in Health and Quality of Life Outcomes, comparing the 3L and 5L versions of EQ-5D…
Valuing Health at the End of Life: A Review of the Empirical Literature
3 November 2015
Do members of the general public wish to place greater weight on a unit of health gain for end of life patients than on that for…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. We explore the feasibility of implementing MIP in the UK.
Waiting Time Policies in the Health Sector: What Works?
27 October 2015
On 16th September Professor Luigi Siciliani led an OHE lunchtime seminar on waiting time policies in the health sector. The slides are now available.
Just Published: Testing the Feasibility of Obtaining EQ-5D-5L Values in the United Arab Emirates
23 October 2015
This study tests the feasibility of eliciting EQ-5D-5L values from a general public sample in the United Arab Emirates.
OHE at ISPOR Latin America: Policy Options for Formulary Development in Middle-income Countries
20 October 2015
This post summarises OHE’s activities at this year’s ISPOR Latin America conference in Santiago, September 2015. Topics include policy options for formulary development in middle-income countries,…
Government and Charity Funding of Cancer Research: Public Preferences and Choices
13 October 2015
How might a change in government spending on cancer research affect the public’s willingness to donate to cancer research charities?
Professor Nancy Devlin Appointed to PHIN’s Board of Directors
9 October 2015
OHE’s Nancy Devlin has been appointed as a Non-Executive Director with the Private Healthcare Information Network (PHIN).
Future Cases of Dementia among People Born in 2015 & the Dementia Drug Pipeline
6 October 2015
It is estimated that one in three people born in 2015 in the UK may develop dementia, and clinical development success rates for dementia drugs are…